Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2004

01.05.2004 | Original Article

Interactions of a herbal combination that inhibits growth of prostate cancer cells

verfasst von: Vinh Q. Chung, Martin Tattersall, H. T. Andrew Cheung

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

PC SPES is an eight-component herbal product marketed for the treatment of prostate cancer. The manufacturer of PC SPES claims that the herbal combination is a synergistic blend, but the purported synergy has never been tested. We examined the interaction in cell culture of these eight individual herbal components by the use of an isobologram.

Methods

US patent no. 5,665,393 (1997) for PC SPES was acquired, and each of the eight herbal components described was acquired, properly identified, and extracted by 95% ethanol. The extracts were tested for cytotoxicity to PC 3 human prostate cancer cells in culture by the MTT (3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Seven combinations of herbal extracts were made, varying in the proportion of the most cytotoxic herbal extract, that of Panax notoginseng. The interactions of P. notoginseng with the other seven herbs were evaluated through the use of an isobologram.

Results

In all seven herbal combinations, P. notoginseng was found to be antagonistic with the other seven herbal components in the cytotoxicity assay (P values: 0.09, 0.12, 0.12, 0.33, 0.45, 0.56, and 0.76).

Conclusions

The interaction between the most cytotoxic herbal component of a widely used herbal product and the other seven components was antagonistic. Herbal combinations are no different from traditional combination pharmacotherapy. If herbal combinations are able to achieve antagonism, then theoretically they can achieve synergism if combined properly.
Literatur
1.
Zurück zum Zitat Bayne CW, Donnelly F, Ross M, Habib FK (1999) Serenoa repens (Permixon): a 5α-reductase types I and II inhibitor—new evidence in a coculture model of BPH. Prostate 40:232–241CrossRefPubMed Bayne CW, Donnelly F, Ross M, Habib FK (1999) Serenoa repens (Permixon): a 5α-reductase types I and II inhibitor—new evidence in a coculture model of BPH. Prostate 40:232–241CrossRefPubMed
2.
Zurück zum Zitat Butenko IG, Gladtchenko SV, Galushko SV (1993) Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis Georgy roots. Agents Actions 39:C49–51PubMed Butenko IG, Gladtchenko SV, Galushko SV (1993) Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis Georgy roots. Agents Actions 39:C49–51PubMed
3.
Zurück zum Zitat Chen S, Wang X (1997) Herbal composition for treating prostate carcinoma. US Patent no. 5,665,393. http://patft.uspto.gov Chen S, Wang X (1997) Herbal composition for treating prostate carcinoma. US Patent no. 5,665,393. http://​patft.​uspto.​gov
4.
Zurück zum Zitat Darzynkiewicz Z, Traganos F, Wu JM, Chen S (2000) Chinese herbal mixture PC SPES in treatment of prostate cancer. Int J Oncol 17:729–736PubMed Darzynkiewicz Z, Traganos F, Wu JM, Chen S (2000) Chinese herbal mixture PC SPES in treatment of prostate cancer. Int J Oncol 17:729–736PubMed
5.
Zurück zum Zitat de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE (1999) Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 84:845–850PubMed de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE (1999) Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 84:845–850PubMed
6.
Zurück zum Zitat de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin DK, Katz AE (2000) Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164:1229–1234PubMed de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin DK, Katz AE (2000) Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164:1229–1234PubMed
7.
Zurück zum Zitat Deckers CLP, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41:1364–1374PubMed Deckers CLP, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41:1364–1374PubMed
8.
Zurück zum Zitat Food and Drug Administration. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. 2002 Safety Information Summaries. http://www.fda.gov/medwatch/SAFETY/2002/safety02.htm#spes Food and Drug Administration. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. 2002 Safety Information Summaries. http://​www.​fda.​gov/​medwatch/​SAFETY/​2002/​safety02.​htm#spes
9.
Zurück zum Zitat Geliebter J, Mittelman A, Tiwari RK (2001) PC-SPES and prostate cancer. J Nutr 131:164S–166SPubMed Geliebter J, Mittelman A, Tiwari RK (2001) PC-SPES and prostate cancer. J Nutr 131:164S–166SPubMed
10.
Zurück zum Zitat Gessner PK (1995) Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105:161–179CrossRefPubMed Gessner PK (1995) Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105:161–179CrossRefPubMed
11.
Zurück zum Zitat Haddock MG, Ames MM, Bonner J (1995) Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin Proc 70:1053–1060PubMed Haddock MG, Ames MM, Bonner J (1995) Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin Proc 70:1053–1060PubMed
12.
Zurück zum Zitat Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16–23PubMed Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16–23PubMed
13.
Zurück zum Zitat Kim J, Amorino GP, Pyo H, Cao Q, Price JO, Choy H (2001) The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys 51:525–534CrossRefPubMed Kim J, Amorino GP, Pyo H, Cao Q, Price JO, Choy H (2001) The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys 51:525–534CrossRefPubMed
14.
Zurück zum Zitat Kim KC, Kim IG (1999) Ganoderma lucidum extract protects DNA from strand breakage caused by hydroxyl radical and UV irradiation. Int J Mol Med 4:273–277PubMed Kim KC, Kim IG (1999) Ganoderma lucidum extract protects DNA from strand breakage caused by hydroxyl radical and UV irradiation. Int J Mol Med 4:273–277PubMed
15.
Zurück zum Zitat Konoshima T, Takasaki M, Tokuda H (1999) Anti-carcinogenic activity of the roots of Panax notoginseng. II. Biol Pharm Bull 22:1150–1152PubMed Konoshima T, Takasaki M, Tokuda H (1999) Anti-carcinogenic activity of the roots of Panax notoginseng. II. Biol Pharm Bull 22:1150–1152PubMed
16.
Zurück zum Zitat Lee JM, Kwon H, Jeong H, Lee JW, Lee SY, Back SJ, Surh YJ (2001) Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res 15:245–249CrossRefPubMed Lee JM, Kwon H, Jeong H, Lee JW, Lee SY, Back SJ, Surh YJ (2001) Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res 15:245–249CrossRefPubMed
17.
Zurück zum Zitat Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW (2001) Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 57:122–126CrossRef Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW (2001) Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 57:122–126CrossRef
18.
Zurück zum Zitat Pfeifer BL, Pirani JF, Hamann SR, Klippel KF (2000) PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 85:481–485CrossRefPubMed Pfeifer BL, Pirani JF, Hamann SR, Klippel KF (2000) PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 85:481–485CrossRefPubMed
19.
Zurück zum Zitat Qin GW, Xu RS (1998) Recent advances in bioactive natural products from Chinese medicinal plants. Med Res Rev 18:375–382CrossRefPubMed Qin GW, Xu RS (1998) Recent advances in bioactive natural products from Chinese medicinal plants. Med Res Rev 18:375–382CrossRefPubMed
20.
Zurück zum Zitat Roks G, Deckers CLP, van Egmond J, Meinardi H, van Rijn CM (1999) Effects of monotherapy and polytherapy with antiepileptic drugs: an animal study. J Pharmacol Exp Ther 288:472–477PubMed Roks G, Deckers CLP, van Egmond J, Meinardi H, van Rijn CM (1999) Effects of monotherapy and polytherapy with antiepileptic drugs: an animal study. J Pharmacol Exp Ther 288:472–477PubMed
21.
Zurück zum Zitat Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE (1994) Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 35:450–460PubMed Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE (1994) Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 35:450–460PubMed
22.
Zurück zum Zitat Shibata S (2000) A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. J Pharm Soc Jpn 120:849–862 Shibata S (2000) A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. J Pharm Soc Jpn 120:849–862
23.
Zurück zum Zitat Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM (2000) Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595–3603PubMed Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM (2000) Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595–3603PubMed
24.
Zurück zum Zitat Sovak M, Seligson A, Konas M, et al (2002) PC-SPES in prostate cancer: an herbal mixture currently containing warfarin and previously diethylstilbestrol and indomethacin (abstract LB152). Annual Meeting of the American Association of Cancer Research, San Francisco Sovak M, Seligson A, Konas M, et al (2002) PC-SPES in prostate cancer: an herbal mixture currently containing warfarin and previously diethylstilbestrol and indomethacin (abstract LB152). Annual Meeting of the American Association of Cancer Research, San Francisco
25.
Zurück zum Zitat Tallarida RJ (2001) Drug synergism: its detection and applications. Perspect Pharmacol 298:865–872 Tallarida RJ (2001) Drug synergism: its detection and applications. Perspect Pharmacol 298:865–872
26.
Zurück zum Zitat Wang RL (1993) A report of 40 cases of esophageal carcinoma surviving for more than 5 years after treatment with drugs. Zhonghua Zhong Liu Za Zhi 15:300–302PubMed Wang RL (1993) A report of 40 cases of esophageal carcinoma surviving for more than 5 years after treatment with drugs. Zhonghua Zhong Liu Za Zhi 15:300–302PubMed
27.
Zurück zum Zitat Wilt TJ, Ishani A, Indulis R, MacDonald R (2000) Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459–472PubMed Wilt TJ, Ishani A, Indulis R, MacDonald R (2000) Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459–472PubMed
Metadaten
Titel
Interactions of a herbal combination that inhibits growth of prostate cancer cells
verfasst von
Vinh Q. Chung
Martin Tattersall
H. T. Andrew Cheung
Publikationsdatum
01.05.2004
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2004
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-003-0746-1

Weitere Artikel der Ausgabe 5/2004

Cancer Chemotherapy and Pharmacology 5/2004 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.